Business Description
Roche Holding AG
ISIN : CH0012032113
Share Class Description:
STU:RHO: Bearer SharesTotal Employee Number:
112,774Compare
Compare
Traded in other countries / regions
ROP.SwitzerlandRHHBY.USA0QOK.UKROCH.CanadaRHO.GermanyROP1N.Mexico1RO.ItalyROGH.Austria IPO Date
2009-09-09Description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 0.97 | |||||
Debt-to-EBITDA | 1.51 | |||||
Interest Coverage | 13.76 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 4.78 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.1 | |||||
3-Year EBITDA Growth Rate | 1.5 | |||||
3-Year EPS without NRI Growth Rate | -1.4 | |||||
3-Year FCF Growth Rate | -0.2 | |||||
3-Year Book Growth Rate | 6.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.54 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.9 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.1 | |||||
9-Day RSI | 58.9 | |||||
14-Day RSI | 58.45 | |||||
3-1 Month Momentum % | 2.47 | |||||
6-1 Month Momentum % | -5.82 | |||||
12-1 Month Momentum % | 22.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.23 | |||||
Quick Ratio | 0.95 | |||||
Cash Ratio | 0.34 | |||||
Days Inventory | 169.62 | |||||
Days Sales Outstanding | 71.93 | |||||
Days Payable | 104.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.79 | |||||
Dividend Payout Ratio | 0.51 | |||||
3-Year Dividend Growth Rate | 1.4 | |||||
Forward Dividend Yield % | 2.79 | |||||
5-Year Yield-on-Cost % | 3.07 | |||||
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | 3.93 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 73.6 | |||||
Operating Margin % | 28.3 | |||||
Net Margin % | 19.6 | |||||
EBITDA Margin % | 33.43 | |||||
FCF Margin % | 22.02 | |||||
OCF Margin % | 30.75 | |||||
ROE % | 38.9 | |||||
ROA % | 12.61 | |||||
ROIC % | 17.86 | |||||
3-Year ROIIC % | 7.28 | |||||
ROC (Joel Greenblatt) % | 70.31 | |||||
ROCE % | 25.31 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 23.3 | |||||
Forward PE Ratio | 17.58 | |||||
PE Ratio without NRI | 18.57 | |||||
Shiller PE Ratio | 25.09 | |||||
Price-to-Owner-Earnings | 21.16 | |||||
PS Ratio | 4.56 | |||||
PB Ratio | 8.7 | |||||
Price-to-Tangible-Book | 50.8 | |||||
Price-to-Free-Cash-Flow | 20.67 | |||||
Price-to-Operating-Cash-Flow | 14.81 | |||||
EV-to-EBIT | 17.5 | |||||
EV-to-Forward-EBIT | 13.72 | |||||
EV-to-EBITDA | 14.65 | |||||
EV-to-Forward-EBITDA | 12.1 | |||||
EV-to-Revenue | 4.9 | |||||
EV-to-Forward-Revenue | 4.74 | |||||
EV-to-FCF | 22.57 | |||||
Price-to-GF-Value | 1.35 | |||||
Price-to-Projected-FCF | 1.78 | |||||
Price-to-Median-PS-Value | 1.09 | |||||
Price-to-Graham-Number | 6.47 | |||||
Earnings Yield (Greenblatt) % | 5.73 | |||||
FCF Yield % | 4.91 | |||||
Forward Rate of Return (Yacktman) % | 2.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Roche Holding AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 67,919.866 | ||
| EPS (TTM) (€) | 16.55 | ||
| Beta | 0.4491 | ||
| 3-Year Sharpe Ratio | 0.66 | ||
| 3-Year Sortino Ratio | 1.48 | ||
| Volatility % | 22.99 | ||
| 14-Day RSI | 58.45 | ||
| 14-Day ATR (€) | 9.775171 | ||
| 20-Day SMA (€) | 374.07 | ||
| 12-1 Month Momentum % | 22.85 | ||
| 52-Week Range (€) | 271.4 - 419.8 | ||
| Shares Outstanding (Mil) | 796.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Roche Holding AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Roche Holding AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-01-29 13:30 | In 182 days | ||
| Fourth quarter earnings results for 2026 | 2027-01-29 07:00 | In 182 days | ||
| Annual report for 2026 | 2027-01-28 | In 180 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-23 14:00 | 360.20 (-1.10%) | ||
| Second quarter earnings results for 2026 | 2026-07-23 | 360.20 (-1.10%) | ||
| Roche’s Virtual ADA Investor Event | 2026-06-08 17:00 | 358.60 (-0.83%) | ||
| CHF 0.999000 Cash Dividend | 2026-03-12 | 375.80 (-1.36%) | ||
| CHF 9.800000 Cash Dividend | 2026-03-12 | 375.80 (-1.36%) | ||
| General meeting for 2026 | 2026-03-10 10:30 | 382.00 (-0.88%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-01-29 13:30 | 373.60 (-4.94%) |
Show
Entries
Roche Holding AG Frequently Asked Questions
What is Roche Holding AG(STU:RHO)'s stock price today?
The current price of STU:RHO is €388.60. The 52 week high of STU:RHO is €419.80 and 52 week low is €271.40.
When is next earnings date of Roche Holding AG(STU:RHO)?
The next earnings date of Roche Holding AG(STU:RHO) is 2027-01-29 Est..
Does Roche Holding AG(STU:RHO) pay dividends? If so, how much?
The Dividend Yield %  of Roche Holding AG(STU:RHO) is 2.79% (As of Today), Highest Dividend Payout Ratio of Roche Holding AG(STU:RHO) was 0.56. The lowest was 0.43. And the median was 0.48. The  Forward Dividend Yield % of Roche Holding AG(STU:RHO) is 2.79%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Roche Holding AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers